Secondary Prophylaxis of Gastric Variceal Bleed

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to study the efficacy of endoscopic cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration in the prevention of gastric variceal rebleeding and improvement in survival.

Official Title
-----------------
Endoscopic Cyanoacrylate Injection vs. Balloon-occluded Retrograde Transvenous Obliteration in the Prevention of Gastric Variceal Rebleeding

Conditions
-----------------
Gastric Varices

Intervention / Treatment
-----------------
* Procedure: Balloon-occluded retrograde transvenous obliteration
* Procedure: Endoscopic cyanoacrylate injection
* Drug: N-butyl-2-cyanoacrylate
* Drug: Lauromacrogol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cirrhosis Patients who had bled from GOV2 or IGV1（≥5 days and ≤ 28days） Presence of gastrorenal shunt Exclusion Criteria: Previous treatment of gastric varices, including endoscopic therapy, NSBB, TIPS, or surgery Non-cirrhotic portal hypertension Contraindications to cyanoacrylate injection or BRTO Portal cavernoma Hepatorenal syndrome Proven malignancy including hepatocellular carcinoma End-stage renal disease under renal replacement therapy; Cardiorespiratory failure Pregnancy or patients not giving informed consent for endoscopic procedures

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: BRTO<br>Balloon-occluded retrograde transvenous obliteration | Procedure: Balloon-occluded retrograde transvenous obliteration<br>* Balloon-occluded retrograde transvenous obliteration<br>Drug: Lauromacrogol<br> <br> |
| Active Comparator: NBCA<br>Endoscopic Cyanoacrylate injection in the gastric varix | Procedure: Endoscopic cyanoacrylate injection<br>* Endoscopic cyanoacrylate injection<br>Drug: N-butyl-2-cyanoacrylate<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rebleeding rate from gastric varices |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Eradication rate of gastric varices |  | 3 years | 
| Number of participants with increase or decrease in the size of gastric varices |  | 3 years | 
| Number of participants with appearance or worsening of new oesophageal varices |  | 3 years | 
| Number of participants with appearance or worsening of portal hypertensive gastropathy |  | 3 years | 
| Number of participants with appearance or worsening of ascites |  | 3 years | 
| Number of participants with complication |  | 3 years | 
| Average in-hospital stay |  | 3 years | 
| Cost of treatment |  | 3 years | 
| Mortality rate |  | 3 years |